iPSCs hold the key to available cell therapies. Yet, developing iPSC-based allogeneic cell therapies presents significant challenges, including immunogenicity, genomic stability, differentiation consistency, and complexities surrounding regulatory compliance and quality control.
Join us for this insightful webinar presented by Peter Jaehn, VP of Business Development for Europe and Asia Pacific, to learn how Cellistic is addressing these critical issues through its advanced technology platforms for Cell Line Development and GMP manufacturing. With 15 years of experience in cell therapy, Cellistic supports therapeutic developers in creating off-the-shelf cell therapy treatments.

 

Key Takeaways for You:

  • Scalability: Discover how the integration of Cellistic’s STAR-CRISPR™, Pulse™, and Echo™ platforms enables seamless scalability in cell therapy development—from initial concept to commercial drug products—while ensuring safe and reliable outcomes at every stage.
  • Cost Efficiency: Learn how these platforms work together to reduce both time and resource expenditures, streamlining development through standardized workflows, automation and expert guidance.
  • Safety and Compliance: Gain insight into the rigorous safety measures and quality controls Cellistic employs to ensure GMP compliance while developing product-specific, gene-edited master cell banks (MCBs) and managing the entire production process—from material sourcing to final cell therapy product delivery.

 

Register for the webinar